Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Nov;62(11):1078–1082. doi: 10.1136/ard.62.11.1078

Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

J Peterson 1, F Hsu 1, P Simkin 1, M Wener 1
PMCID: PMC1754346  PMID: 14583571

Abstract

Background: Tumour necrosis factor α (TNFα) antagonists are effective for the treatment of rheumatoid arthritis (RA), but concerns remain about the safety of these agents in the presence of chronic infections, including hepatitis C virus (HCV) infection.

Objective: To examine the influence of treatment with TNFα antagonists on levels of HCV viraemia and serum transaminases in patients with RA and HCV.

Methods: In a retrospective survey the course of 16 HCV infected patients with RA who had received the TNFα antagonists etanercept or infliximab was analysed. Eight additional patients with RA and HCV were also enrolled into a three month prospective trial of etanercept. Serum concentrations of albumin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and HCV were followed.

Results: Viraemia was measured in 22 patients receiving a TNFα antagonist at the start of treatment and after 1–34 months (median 9 months follow up). Twenty four patients had serial tests of liver related enzymes and albumin. None of the differences between liver related tests at baseline and at follow up achieved significance (p>0.05). Similarly, the mean HCV measurement at 1–3, 4–6, 7–12, and 13–34 months did not differ significantly from baseline (p>0.05).

Conclusion: In this study, liver related blood tests and HCV viral load measurements did not change substantially. These findings suggest that TNFα antagonists merit further study for the treatment of RA in HCV infected patients. Larger and longer term studies are still needed.

Full Text

The Full Text of this article is available as a PDF (270.2 KB).

Figure 1 .

Figure 1

Open in a new tab

Measurement of plasma viraemia before and after starting TNFα antagonists. A TNFα antagonist was started at time=0. Data from cases with (A) <5-fold; (B) 5-10-fold; (C) >10-fold change between maximum and minimum level of plasma viraemia. For one case, plasma viraemia was present at the beginning of the study and at the end of follow up, but undetectable (signified by the asterisk *) at one and three months after starting etanercept. Overall, no significant change was seen in the average levels of viraemia while taking TNFα antagonists.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aardema K. L., Nakhleh R. E., Terry L. K., Burd E. M., Ma C. K., Moonka D. K., Brown K. A., Abouljoud M. S. Tissue quantification of hepatitis C virus RNA with morphologic correlation in the diagnosis of recurrent hepatitis C virus in human liver transplants. Mod Pathol. 1999 Nov;12(11):1043–1049. [PubMed] [Google Scholar]
  2. Aboulafia D. M., Bundow D., Wilske K., Ochs U. I. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc. 2000 Oct;75(10):1093–1098. doi: 10.4065/75.10.1093. [DOI] [PubMed] [Google Scholar]
  3. Arase Y., Ikeda K., Chayama K., Murashima N., Tsubota A., Suzuki Y., Saitoh S., Kobayashi M., Kobayashi M., Suzuki F. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol. 2000;35(3):221–225. doi: 10.1007/s005350050334. [DOI] [PubMed] [Google Scholar]
  4. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  5. Assy N., Minuk G. Y. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol. 2000 Jun;95(6):1545–1550. doi: 10.1111/j.1572-0241.2000.02027.x. [DOI] [PubMed] [Google Scholar]
  6. Baffoni L., Frisoni M., Miniero R., Righetti F., Sprovieri G., Ferri S. True positive anti-HCV tests in rheumatoid arthritis. Br J Rheumatol. 1993 Apr;32(4):349–350. doi: 10.1093/rheumatology/32.4.349-a. [DOI] [PubMed] [Google Scholar]
  7. Bekker L. G., Freeman S., Murray P. J., Ryffel B., Kaplan G. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol. 2001 Jun 1;166(11):6728–6734. doi: 10.4049/jimmunol.166.11.6728. [DOI] [PubMed] [Google Scholar]
  8. Berenguer M., López-Labrador F. X., Wright T. L. Hepatitis C and liver transplantation. J Hepatol. 2001 Nov;35(5):666–678. doi: 10.1016/s0168-8278(01)00179-9. [DOI] [PubMed] [Google Scholar]
  9. Biancone Livia, Del Vecchio Blanco Giovanna, Pallone Francesco, Castiglione Fabiana, Bresci Giampaolo, Sturniolo Giancarlo, Italian Group for the Study of the Colon and Rectum Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology. 2002 Feb;122(2):593–594. doi: 10.1053/gast.2002.31602. [DOI] [PubMed] [Google Scholar]
  10. Cahen D. L., van Leeuwen D. J., ten Kate F. J., Blok A. P., Oosting J., Chamuleau R. A. Do serum ALAT values reflect the inflammatory activity in the liver of patients with chronic viral hepatitis? Liver. 1996 Apr;16(2):105–109. doi: 10.1111/j.1600-0676.1996.tb00713.x. [DOI] [PubMed] [Google Scholar]
  11. Campbell S., Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 2001 Feb;13(2):191–192. doi: 10.1097/00042737-200102000-00016. [DOI] [PubMed] [Google Scholar]
  12. Chayama K., Tsubota A., Kobayashi M., Hashimoto M., Miyano Y., Koike H., Kobayashi M., Koida I., Arase Y., Saitoh S. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Hepatology. 1996 May;23(5):953–957. doi: 10.1053/jhep.1996.v23.pm0008621174. [DOI] [PubMed] [Google Scholar]
  13. Costes V., Durand L., Pageaux G. P., Ducos J., Mondain A. M., Picot M. C., Domergue J., Larrey D., Baldet P. Hepatitis C virus genotypes and quantification of serum hepatitis C RNA in liver transplant recipients. Relationship with histologic outcome of recurrent hepatitis C. Am J Clin Pathol. 1999 Feb;111(2):252–258. doi: 10.1093/ajcp/111.2.252. [DOI] [PubMed] [Google Scholar]
  14. Criscione Lisa G., St Clair E. William. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2002 May;14(3):204–211. doi: 10.1097/00002281-200205000-00002. [DOI] [PubMed] [Google Scholar]
  15. Duvoux C., Pawlotsky J. M., Cherqui D., Tran van Nhieu J., Metreau J. M., Fagniez P. L., Duval J., Zafrani E. S., Dhumeaux D. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. A useful test for diagnosis of hepatitis C virus reinfection. Transplantation. 1995 Sep 15;60(5):457–461. doi: 10.1097/00007890-199509000-00009. [DOI] [PubMed] [Google Scholar]
  16. Fanning L., Loane J., Kenny-Walsh E., Sheehan M., Whelton M., Kirwan W., Collins J. K., Shanahan F. Tissue viral load variability in chronic hepatitis C. Am J Gastroenterol. 2001 Dec;96(12):3384–3389. doi: 10.1111/j.1572-0241.2001.05271.x. [DOI] [PubMed] [Google Scholar]
  17. Felson D. T., Anderson J. J., Boers M., Bombardier C., Furst D., Goldsmith C., Katz L. M., Lightfoot R., Jr, Paulus H., Strand V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727–735. doi: 10.1002/art.1780380602. [DOI] [PubMed] [Google Scholar]
  18. Fisher C. J., Jr, Agosti J. M., Opal S. M., Lowry S. F., Balk R. A., Sadoff J. C., Abraham E., Schein R. M., Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996 Jun 27;334(26):1697–1702. doi: 10.1056/NEJM199606273342603. [DOI] [PubMed] [Google Scholar]
  19. Fukumoto T., Berg T., Ku Y., Bechstein W. O., Knoop M., Lemmens H. P., Lobeck H., Hopf U., Neuhaus P. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology. 1996 Dec;24(6):1351–1354. doi: 10.1002/hep.510240606. [DOI] [PubMed] [Google Scholar]
  20. Furst D. E., Keystone E., Maini R. N., Smolen J. S. Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999 Nov;38 (Suppl 2):50–53. [PubMed] [Google Scholar]
  21. Gane E. J., Naoumov N. V., Qian K. P., Mondelli M. U., Maertens G., Portmann B. C., Lau J. Y., Williams R. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996 Jan;110(1):167–177. doi: 10.1053/gast.1996.v110.pm8536853. [DOI] [PubMed] [Google Scholar]
  22. Gretch D. R., Bacchi C. E., Corey L., dela Rosa C., Lesniewski R. R., Kowdley K., Gown A., Frank I., Perkins J. D., Carithers R. L., Jr Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology. 1995 Jul;22(1):1–9. [PubMed] [Google Scholar]
  23. Gugenheim J., Baldini E., Mazza D., Fabiani P., St Paul M. C., Goubaux B., Ouzan D., Mouiel J. Recurrence of hepatitis C virus after liver transplantation. Transpl Int. 1994;7 (Suppl 1):S224–S226. doi: 10.1111/j.1432-2277.1994.tb01352.x. [DOI] [PubMed] [Google Scholar]
  24. Guilera M., Forns X., Torras X., Enríquez J., Coll S., Solà R., Morillas R., Planas R., Ampurdanès S., Soler M. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. J Hepatol. 2000 Jul;33(1):135–141. doi: 10.1016/s0168-8278(00)80170-1. [DOI] [PubMed] [Google Scholar]
  25. Herbein G., O'Brien W. A. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med. 2000 Mar;223(3):241–257. doi: 10.1177/153537020022300305. [DOI] [PubMed] [Google Scholar]
  26. Hochberg M. C., Chang R. W., Dwosh I., Lindsey S., Pincus T., Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992 May;35(5):498–502. doi: 10.1002/art.1780350502. [DOI] [PubMed] [Google Scholar]
  27. Keane J., Gershon S., Wise R. P., Mirabile-Levens E., Kasznica J., Schwieterman W. D., Siegel J. N., Braun M. M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098–1104. doi: 10.1056/NEJMoa011110. [DOI] [PubMed] [Google Scholar]
  28. Magrin S., Craxi A., Fabiano C., Simonetti R. G., Fiorentino G., Marino L., Diquattro O., Di Marco V., Loiacono O., Volpes R. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology. 1994 Feb;19(2):273–279. [PubMed] [Google Scholar]
  29. McCaughan G. W., Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl Infect Dis. 2000 Dec;2(4):166–185. doi: 10.1034/j.1399-3062.2000.020403.x. [DOI] [PubMed] [Google Scholar]
  30. Mok M. Y., Ng W. L., Yuen M. F., Wong R. W., Lau C. S. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol. 2000 May-Jun;18(3):363–368. [PubMed] [Google Scholar]
  31. Roach Daniel R., Bean Andrew G. D., Demangel Caroline, France Malcolm P., Briscoe Helen, Britton Warwick J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002 May 1;168(9):4620–4627. doi: 10.4049/jimmunol.168.9.4620. [DOI] [PubMed] [Google Scholar]
  32. Rodríguez-Rosado R., Pérez-Olmeda M., García-Samaniego J., Soriano V. Management of hepatitis C in HIV-infected persons. Antiviral Res. 2001 Nov;52(2):189–198. doi: 10.1016/s0166-3542(01)00184-x. [DOI] [PubMed] [Google Scholar]
  33. Schlüter D., Deckert M. The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes Infect. 2000 Aug;2(10):1285–1292. doi: 10.1016/s1286-4579(00)01282-x. [DOI] [PubMed] [Google Scholar]
  34. Sheth S. G., Flamm S. L., Gordon F. D., Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998 Jan;93(1):44–48. doi: 10.1111/j.1572-0241.1998.044_c.x. [DOI] [PubMed] [Google Scholar]
  35. Shiffman M. L., Hofmann C. M., Thompson E. B., Ferreira-Gonzalez A., Contos M. J., Koshy A., Luketic V. A., Sanyal A. J., Mills A. S., Garrett C. T. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology. 1997 Sep;26(3):780–785. doi: 10.1002/hep.510260335. [DOI] [PubMed] [Google Scholar]
  36. Suzuki Y., Uehara R., Tajima C., Noguchi A., Ide M., Ichikawa Y., Mizushima Y. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol. 1999;28(5):273–281. doi: 10.1080/03009749950155454. [DOI] [PubMed] [Google Scholar]
  37. Walker R. E., Spooner K. M., Kelly G., McCloskey R. V., Woody J. N., Falloon J., Baseler M., Piscitelli S. C., Davey R. T., Jr, Polis M. A. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis. 1996 Jul;174(1):63–68. doi: 10.1093/infdis/174.1.63. [DOI] [PubMed] [Google Scholar]
  38. Zhu N., Khoshnan A., Schneider R., Matsumoto M., Dennert G., Ware C., Lai M. M. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol. 1998 May;72(5):3691–3697. doi: 10.1128/jvi.72.5.3691-3697.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES